GB1354097A - Isoxazole derivatives - Google Patents
Isoxazole derivativesInfo
- Publication number
- GB1354097A GB1354097A GB1106371*[A GB1106371A GB1354097A GB 1354097 A GB1354097 A GB 1354097A GB 1106371 A GB1106371 A GB 1106371A GB 1354097 A GB1354097 A GB 1354097A
- Authority
- GB
- United Kingdom
- Prior art keywords
- group
- corresponding compound
- optionally substituted
- substituted amino
- methyl
- Prior art date
- Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
- Expired
Links
Classifications
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D413/00—Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and oxygen atoms as the only ring hetero atoms
- C07D413/02—Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and oxygen atoms as the only ring hetero atoms containing two hetero rings
- C07D413/12—Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and oxygen atoms as the only ring hetero atoms containing two hetero rings linked by a chain containing hetero atoms as chain links
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D413/00—Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and oxygen atoms as the only ring hetero atoms
- C07D413/14—Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and oxygen atoms as the only ring hetero atoms containing three or more hetero rings
Landscapes
- Chemical & Material Sciences (AREA)
- Organic Chemistry (AREA)
- Heterocyclic Carbon Compounds Containing A Hetero Ring Having Nitrogen And Oxygen As The Only Ring Hetero Atoms (AREA)
Abstract
1354097 Naphth-[1,2-c]isoxazoles TEIKOKU HORMONE MFG CO Ltd 23 April 1971 [24 April 1970 (3) 30 Jan 1971 16 March 1971 19 March 1971 20 March 1971 (2) 20 April 1971] 11063/71 Heading C2C Novel naphth-[1,2-c] isoxazoles of the general formula wherein ring A is optionally substituted, ring B optionally contains a 4,5-double bond and R is a methyl, hydroxymethyl, (optionally substituted alkoxy) methyl, (optionally substituted amino)- alkoxymethyl, halomethyl, (optionally substituted amino)-methyl or cyano group or a group of the formula -C(=Y)-R 1 , where R 1 is a hydroxy, optionally substituted amino or C 1-12 hydrocarbyloxy or hydrocarbyl group, or a group of the formula -OM1/12, where M is an alkali metal, alkaline earth metal or aluminium atom, an ammonium group or an organic base cation and n is the valency of M, or a group of formula -O(AlOH)¢, and Y is an oxygen or sulphur atom, Y being an oxygen atom when R 1 is a hydroxy, hydrocarbyloxy or -OM1/12 group, and acid addition salts thereof are prepared (a) by cyclization of a 1-hydroxylimino-1,2-dihydronaphthalene of the general formula wherein ring B<SP>1</SP> optionally contains a 3,4-double bond; (b) when R is a -COOH group by hydrolysis or hydrogenolysis of the corresponding compound in which R is -COR 1 and R 1 is a hydrocarbyloxy group or hydrolysis of the corresponding compound in which R is a cyano or COR 1 group and R 1 is an optionally substituted amino group; (c) when R is a -COOM1/12 or -COO(AlOH)¢ group, by reaction of the corresponding compound in which R is a -COOH group with an alkali metal, alkaline earth metal or aluminium hydroxide or alkoxide, an organometallic compound containing a bond between an alkali or alkaline earth metal or aluminium and carbon, ammonia or an organic base; (d) when R is a -COR 1 group and R 1 is an optionally substituted amino group, by reaction of the corresponding compound in which R is a -COOH group or a functional derivative thereof (e.g. the acid halide or acid anhydride, the latter being produced from the free acid by dehydration with ammonia or an amine, or when R is a -CONH 2 group, by partial hydrolysis of the corresponding compound in which R is a cyano group; (e) when R is a -CS-R 1 group, by conversion in a manner known per se of the corresponding compound in which R is a -CO-R 1 group; (f) when R is a hydroxymethyl group, by hydrogenation of the corresponding compound in which R is a -COOH or -CO-R 1 group and R 1 is a hydrocarbyloxy group; (g) when R is a halomethyl group, by conversion in a manner known per se of the corresponding compound in which R is a hydroxymethyl group; (h) when R is a methyl group, by hydrogenation of the corresponding compound in which R is a halomethyl group; (i) when R is an (optionally substituted alkoxy)-methyl or (optionally substituted amino) alkoxymethyl group, by reaction of the corresponding compound in which R is a halomethyl group with an alkali metal (optionally substituted) alkoxide or (optionally substituted amino)-alkoxide; (j) when R is an (optionally substituted amino)- methyl group, by reaction of the corresponding compound in which R is a halomethyl or ptoluene sulphonyloxymethyl group (the sulphonates being produced by reaction of the corresponding compound in which R is a hydroxymethyl group with p-toluenesulphonyl chloride) with ammonia, an amine or an amine alkali metal salt or by hydrogenation of the corresponding compound in which R is a -CO-R 1 group and R 1 is an optionally substituted amino group; (k) when R is a cyano group, by dehydration of the corresponding compound in which R is a -CONH 2 group; and (1) when R is a COR 1 group and R 1 is a hydrocarbyloxy group by esterification of the corresponding compound in which R 1 is a hydroxy group, e.g. via the corresponding acid halide; followed optionally by salification of the resulting free base with an acid. Pharmaceutical compositions having antiphlogistic, gastric juice secretion inhibiting and anti-ulcer activity comprise, as active ingredient, a naphth-(1,2-c] isoxazole of the first general formula above or an acid addition salt thereof, together with a pharmaceutically acceptable carrier or diluent.
Applications Claiming Priority (9)
Application Number | Priority Date | Filing Date | Title |
---|---|---|---|
JP3474470A JPS4911217B1 (en) | 1970-04-24 | 1970-04-24 | |
JP3474670 | 1970-04-24 | ||
JP3474570 | 1970-04-24 | ||
JP318071 | 1971-01-30 | ||
JP1428371 | 1971-03-16 | ||
JP1529771 | 1971-03-19 | ||
JP1567671 | 1971-03-20 | ||
JP1567771 | 1971-03-20 | ||
JP2498071 | 1971-04-20 |
Publications (1)
Publication Number | Publication Date |
---|---|
GB1354097A true GB1354097A (en) | 1974-06-05 |
Family
ID=27576463
Family Applications (1)
Application Number | Title | Priority Date | Filing Date |
---|---|---|---|
GB1106371*[A Expired GB1354097A (en) | 1970-04-24 | 1971-04-23 | Isoxazole derivatives |
Country Status (1)
Country | Link |
---|---|
GB (1) | GB1354097A (en) |
Cited By (4)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
US9216972B2 (en) | 2009-10-29 | 2015-12-22 | Bristol-Myers Squibb Company | Tricyclic heterocyclic compounds |
US10633354B2 (en) | 2016-09-02 | 2020-04-28 | Bristol-Myers Squibb Company | Substituted tricyclic heterocyclic compounds |
US11046646B2 (en) | 2017-08-09 | 2021-06-29 | Bristol-Myers Squibb Company | Alkylphenyl compounds |
US11059784B2 (en) | 2017-08-09 | 2021-07-13 | Bristol-Myers Squibb Company | Oxime ether compounds |
-
1971
- 1971-04-23 GB GB1106371*[A patent/GB1354097A/en not_active Expired
Cited By (4)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
US9216972B2 (en) | 2009-10-29 | 2015-12-22 | Bristol-Myers Squibb Company | Tricyclic heterocyclic compounds |
US10633354B2 (en) | 2016-09-02 | 2020-04-28 | Bristol-Myers Squibb Company | Substituted tricyclic heterocyclic compounds |
US11046646B2 (en) | 2017-08-09 | 2021-06-29 | Bristol-Myers Squibb Company | Alkylphenyl compounds |
US11059784B2 (en) | 2017-08-09 | 2021-07-13 | Bristol-Myers Squibb Company | Oxime ether compounds |
Similar Documents
Publication | Publication Date | Title |
---|---|---|
GB1465229A (en) | Cyclic amino acids | |
GB1447599A (en) | Derivatives of alpha-methyldopa | |
GB1437136A (en) | Anti-inflammatory thiazole compounds compositions and methods for using same | |
GB1305273A (en) | ||
GB1354097A (en) | Isoxazole derivatives | |
GB1456627A (en) | Pyridobenzodiazepinones | |
GB1461020A (en) | Biguanides | |
GB1297386A (en) | ||
AU566342B2 (en) | Tetralin derivatives | |
GB1473971A (en) | 3-hydroxy-5,6-benzomorphinan derivatives | |
GB1529403A (en) | Isoxazole derivative | |
GB1508669A (en) | Methanoanthracene derivative and a process for the preparation thereof | |
GB1222179A (en) | A process for the preparation of sulfonyl urea derivatives | |
GB1412932A (en) | Pharmaceutically active leurosine derivatives and preparation thereof | |
GB1205094A (en) | Improvements in or relating to the treatment of hypertension | |
GB1417946A (en) | Phthalazinone compounds | |
GB1445127A (en) | Benzocycloheptathiophene derivatives | |
SE7408868L (en) | ||
GB1322069A (en) | Aminoalkanoylaminocyclohexane derivatives | |
GB1472344A (en) | Methylene dibenzocycloheptanes | |
GB1301367A (en) | ||
JPS51115402A (en) | Process for preparation of alpha-amino acid | |
GB1384523A (en) | Oxime derivatives and their preparation | |
GB1366554A (en) | Phenylalanine derivatives and a process for their preparation | |
IL43684A (en) | N-propionyl-l-4-hydroxy-proline and salts thereof,a process for their preparation and pharmaceutical compositions containing them |
Legal Events
Date | Code | Title | Description |
---|---|---|---|
PS | Patent sealed [section 19, patents act 1949] | ||
429A | Application made for amendment of specification (sect. 29/1949) | ||
429H | Application (made) for amendment of specification now open to opposition (sect. 29/1949) | ||
429D | Case decided by the comptroller ** specification amended (sect. 29/1949) | ||
PLNP | Patent lapsed through nonpayment of renewal fees |